Sweden's Karo Snaps Up LEO's OTC Derma Brands
Karo Pharma will pay LEO Pharma €90m for a basket of dermatology and anti-hemorrhoid brands to expand its European footprint.
You may also be interested in...
Consumer health first-quarter results round-up featuring Karo Pharma, Boiron and Ipsen.
Generics giant Teva has divested a portfolio of OTC brands marketed in the Nordics to Sweden's Karo, which has been distributing the products in the region for the past 18 months.
HBW Insight reveals the biggest consumer health deals of 2020, and identifies growing private equity investment, portfolio streamlining by major players and pharma firms exiting OTC as the major drivers of M&A activity.